LONDON, September 15, 2026--(BUSINESS WIRE)--Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration with an ...

The deal hinges on Ori’s Iro technology, which combines proprietary hardware, consumables, software and data analytics in a closed system to help automate the production processes for cell and gene ...

The success of the mRNA vaccines for COVID-19 led to explosive growth in lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As these projects scale into clinical trials ...

The track by which API manufacturing processes are prepared for commercial use is comparable to overlapping integrative process evaluations at commercial scale. This ensures the process is ...

The biopharmaceutical industry is expanding rapidly, driven by an increasing demand for complex biomedicines. Today, manufacturing biomolecules presents unique challenges, like cost pressure and ...

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

The quality of a drug product is determined by the manufacturing line. Preclinical assessments and clinical trials provide an indication of safety and efficacy, but it is the manufacturing process ...

Cell and gene therapy manufacturing relies on complex cell processing, viral vector production, quality control, and GMP-compliant workflows to consistently produce safe and effective therapies at ...

Successful startup of Battery Line 2 supports repeatable manufacturing platform, expands production capacity, and advances path toward 4 GWh annualized capacity PITTSBURGH, June 16, 2026 (GLOBE ...